Broncholin Salvae (Syrup) Instructions for Use

Marketing Authorization Holder

Khimpharm, JSC (Kazakhstan)

ATC Code

R03CK (Adrenergics in combination with other drugs for the treatment of obstructive airway diseases)

Active Substances

Salvia (BP British Pharmacopoeia)

Ephedrine (BAN British Approved Name)

Glaucine (BP British Pharmacopoeia)

Dosage Form

Broncholin Salvia

Syrup 5 mg+4 mg+5 mg/5 ml: bottle 125 g

Dosage Form, Packaging, and Composition

125 g – dark glass bottles (1) – cardboard packages.

Clinical-Pharmacological Group

A drug with antitussive and bronchodilator action

Pharmacotherapeutic Group

Combined antitussive agent (sympathomimetic agent+antitussive agent+H1-histamine receptor blocker)

Pharmacological Action

A combined medicinal product that has antitussive, bronchodilator, and expectorant action.

Glaucine is an antitussive agent that acts on the peripheral links of the cough reflex, suppressing the sensitive receptors of the respiratory tract mucosa.

Ephedrine is a sympathomimetic agent that has bronchodilator, vasoconstrictor, and psychostimulant action.

Salvia has expectorant, antitussive, anti-inflammatory, antimicrobial, and antispasmodic action.

Pharmacokinetics

Glaucine and Ephedrine are well absorbed in the digestive tract, creating and maintaining the necessary therapeutic levels in the blood plasma. They are excreted mainly in the urine.

Indications

Diseases of the respiratory tract: tracheitis; bronchitis; pneumonia; bronchial asthma; whooping cough.

ICD codes

Dosage Regimen

Administer the syrup orally.

For adults, take 15 ml three to four times daily.

For children over 10 years of age, administer 10 ml three times daily.

For children over 3 years of age, administer 5 ml three times daily.

The maximum daily frequency for all patient groups is four doses.

Adhere strictly to the prescribed dosing schedule.

Use the provided measuring cup or oral syringe for accurate dose measurement.

Do not exceed the recommended duration of therapy without medical supervision.

Discontinue use and consult a physician if symptoms persist or worsen.

Adverse Reactions

Systemic reactions allergic reactions, weakness, sweating, mydriasis.

From the cardiovascular system palpitations, increased blood pressure.

From the nervous system increased nervous excitability, insomnia, dizziness.

From the digestive system nausea, inhibition of intestinal peristalsis.

From the urinary system difficulty urinating.

Other: drowsiness is possible in children.

Contraindications

Hypersensitivity; angina pectoris; thyrotoxicosis; arterial hypertension; pheochromocytoma; glaucoma; diabetes mellitus; prostate adenoma; insomnia; pregnancy; lactation period; children under 3 years of age.

Use in Pregnancy and Lactation

Contraindicated during pregnancy and lactation (breastfeeding).

Pediatric Use

Contraindicated in children under 3 years of age.

Drug Interactions

With the combined use of ephedrine with MAO inhibitors, severe hypertensive crises may occur due to the suppression of the metabolism of these vasopressor substances.

Ephedrine weakens the effect of opioid analgesics and other agents that depress the CNS. With simultaneous use with non-selective beta-blockers, the bronchodilator effect of this combination is reduced.

Storage Conditions

Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.

Dispensing Status

Rx Only

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.